1. Photoangioplasty Recount: Clear Punch or Dimpled Chad?
- Author
-
Harry Sahota and Nicholas Kipshidze
- Subjects
Peripheral Vascular Diseases ,medicine.medical_specialty ,Photosensitizing Agents ,Arterial disease ,business.industry ,medicine.medical_treatment ,Photodynamic therapy ,Limiting ,medicine.disease ,Surgery ,Stenosis ,Photochemotherapy ,Smooth muscle ,Physiology (medical) ,Plaque volume ,medicine ,Humans ,Cardiology and Cardiovascular Medicine ,Single lesion ,business ,Calcified Material - Abstract
To the Editor: The recent article by Rockson, et al1 presents the results of a phase I trial of photodynamic therapy in patients with peripheral arterial disease. This report seems to be based on preliminary data that do not provide convincing evidence to support its conclusion, ie, that photoangioplasty holds promise as an alternative intervention for flow-limiting atherosclerosis. The lack of a control group and limiting the intervention to a single lesion that is not necessarily a flow-limiting stenosis are especially problematic. Smooth muscle cells constitute no more than 2% to 5% of the volume of the atherosclerotic plaque. Consequently, there is no basis for assuming that the cytotoxic effect of photodynamic therapy would reduce the plaque volume sufficiently to be hemodynamically significant. Even if these cells are killed and lysed, an explanation as to what happened afterward to the major extracellular components of the plaque (cholesterol deposits and fibrous and calcified material) seems necessary and important. Because there are …
- Published
- 2001
- Full Text
- View/download PDF